Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline.

[1]  E. Israel,et al.  Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. , 2021, The New England journal of medicine.

[2]  I. Pavord,et al.  Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline , 2020, Allergy.

[3]  G. Canonica,et al.  Minimal clinically important difference for asthma endpoints: an expert consensus report , 2020, European Respiratory Review.

[4]  I. Pavord,et al.  Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Allergic Asthma. , 2020, The journal of allergy and clinical immunology. In practice.

[5]  A. Murphy,et al.  Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation , 2019, Allergy.

[6]  I. Pavord,et al.  Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology. , 2019, American journal of respiratory and critical care medicine.

[7]  E. Bleecker,et al.  Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids , 2018, The Journal of allergy and clinical immunology.

[8]  J. Virchow,et al.  Impact of an increase in the inhaled corticosteroid dose on blood eosinophils in asthma , 2018, Thorax.

[9]  F. E. Lee,et al.  Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease , 2018, Clinical Reviews in Allergy & Immunology.

[10]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[11]  K. Rabe,et al.  Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.

[12]  D. Price,et al.  Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population , 2017, Thorax.

[13]  Todor A Popov,et al.  Identifying Risk of Future Asthma Attacks Using UK Medical Record Data: A Respiratory Effectiveness Group Initiative. , 2017, The journal of allergy and clinical immunology. In practice.

[14]  F. Albers,et al.  Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. , 2017, The Lancet. Respiratory medicine.

[15]  N. Graham,et al.  Commonality of the IL-4/IL-13 pathway in atopic diseases , 2017, Expert review of clinical immunology.

[16]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[17]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[18]  J. Corren,et al.  Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. , 2016, Chest.

[19]  W. Assendelft,et al.  Identifying patients at risk for severe exacerbations of asthma: development and external validation of a multivariable prediction model , 2016, Thorax.

[20]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[21]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[22]  E. Hauben,et al.  Association between Group 2 Innate Lymphoid Cells enrichment, nasal polyps and allergy in Chronic Rhinosinusitis , 2014, Allergy.

[23]  L. Macdonald,et al.  Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice , 2014, Proceedings of the National Academy of Sciences.

[24]  F. Alt,et al.  Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes , 2014, Proceedings of the National Academy of Sciences.

[25]  J. Fahy.  Type 2 inflammation in asthma — present in most, absent in many , 2014, Nature Reviews Immunology.

[26]  R. Schlosser,et al.  Cytokine correlation between sinus tissue and nasal secretions among chronic rhinosinusitis and controls , 2013, The Laryngoscope.

[27]  A. Zwinderman,et al.  Severe adult-onset asthma: A distinct phenotype. , 2013, The Journal of allergy and clinical immunology.

[28]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[29]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[30]  L. Boulet,et al.  Asthma-related comorbidities , 2011, Expert review of respiratory medicine.

[31]  L. Boulet,et al.  Comparative clinical and airway inflammatory features of asthmatics with or without polyps. , 2010, Rhinology.

[32]  J. L. Hermosa,et al.  Factors Associated With the Control of Severe Asthma , 2010, The Journal of asthma : official journal of the Association for the Care of Asthma.

[33]  G. Viegi,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 * , 2008, Allergy.

[34]  D. Voehringer,et al.  Type 2 immunity is controlled by IL-4/IL-13 expression in hematopoietic non-eosinophil cells of the innate immune system , 2006, The Journal of experimental medicine.

[35]  A. Zwinderman,et al.  Risk factors of frequent exacerbations in difficult-to-treat asthma , 2005, European Respiratory Journal.

[36]  J. Hankinson,et al.  Interpretative strategies for lung function tests , 2005, European Respiratory Journal.

[37]  R. Pauwels,et al.  Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. , 2004, American journal of respiratory and critical care medicine.

[38]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.